The US Food and Drug Administration (FDA) approval of Eisai and Biogen’s LEQEMBI® (lecanemab-irmb) represents a transformative milestone in Alzheimer’s treatment—LEQEMBI is one of the first drugs clinically proven to slow cognitive decline stemming from the disease. Additionally, Eli Lilly’s donanemab has produced similar results and is poised for FDA approval in early 2024.
Based on AlphaSense’s Experts Insights, these exciting developments suggest the industry is primed for continued innovation with an increasing focus on early Alzheimer’s intervention, prevention, and combination therapies.
Download our report to discover expert insights on the evolving Alzheimer’s treatment landscape.
